Table 1

Summary of the 101 STS cases studied

VariableTotalOnly Met
Lrec + Met
Only Lrec
DFS
Total
TotalDeadTotalDeadTotalDeadTotalDeadDead
Total101 (65, 16)41 (21, 9)40 (21, 8)12 (9, 1)12 (9, 1)13 (10, 1)4 (3, 1)35 (25, 5)6 (5, 1)62 (38, 11)
Clinical
    SexFemale54 (30, 8)21 (8, 5)21 (8, 5)8 (5, 1)8 (5, 1)8 (5, 1)3 (2, 1)17 (12, 1)2 (1, 1)34 (16, 8)
Male47 (35, 8)20 (13, 4)19 (13, 3)4 (4, 0)4 (4, 0)5 (4, 0)1 (1, 0)18 (13, 4)4 (4, 0)28 (22, 3)
    DepthS.c.22 (15, 2)4 (1, 1)3 (1, 0)1 (0, 0)1 (0, 0)3 (3, 0)1 (1, 0)14 (11, 1)4 (4, 0)9 (7, 0)
I.m.45 (26, 10)19 (9, 5)19 (9, 5)4 (4, 0)4 (4, 0)8 (5, 1)2 (1, 1)14 (8, 4)2 (1, 1)27 (15, 7)
Extracompartmental26 (17, 3)12 (6, 2)12 (6, 2)6 (4, 1)6 (4, 1)2 (2, 0)1 (1, 0)6 (5, 0)0 (0, 0)19 (11, 3)
    Size (cm)≤632 (22, 4)3 (1, 1)3 (1, 1)5 (3, 1)5 (3, 1)3 (2, 0)0 (0, 0)21 (16, 2)4 (4, 0)12 (8, 2)
7-1123 (17, 3)9 (6, 2)9 (6, 2)1 (1, 0)1 (1, 0)5 (5, 0)2 (2, 0)8 (5, 1)1 (0, 1)13 (9, 3)
>1133 (21, 6)19 (11, 3)19 (11, 3)4 (4, 0)4 (4, 0)5 (3, 1)2 (1, 1)5 (3, 2)1 (1, 0)26 (17, 4)
    Surgical marginWide44 (26, 8)17 (7, 4)17 (7, 4)3 (2, 0)3 (2, 0)6 (4, 1)2 (1, 1)18 (13, 3)6 (5, 1)28 (15, 6)
Marginal31 (19, 6)10 (3, 4)9 (3, 3)4 (4, 0)4 (4, 0)5 (4, 0)0 (0, 0)12 (8, 2)0 (0, 0)13 (7, 3)
Intralesional17 (12, 1)7 (5, 0)7 (5, 0)4 (2, 1)4 (2, 1)2 (2, 0)2 (2, 0)4 (3, 0)0 (0, 0)13 (9, 1)
Histopathological
    Malignancy gradeGrade 338 (22, 7)12 (5, 3)12 (5, 3)8 (5, 1)8 (5, 1)6 (5, 0)0 (0, 0)12 (7, 3)2 (1, 1)22 (11, 5)
Grade 463 (43, 9)29 (16, 6)28 (16, 5)4 (4, 0)4 (4, 0)7 (5, 1)4 (3, 1)23 (18, 2)4 (4, 0)40 (27, 6)
    NecrosesYes77 (51, 12)35 (18, 8)34 (18, 7)9 (7, 1)9 (7, 1)11 (8, 1)4 (3, 1)22 (18, 2)4 (3, 1)51 (31, 10)
No24 (14, 4)6 (3, 1)6 (3, 1)3 (2, 0)3 (2, 0)2 (2, 0)0 (0, 0)13 (7, 3)2 (2, 0)11 (7, 1)
    Mitosis0-2 per HPF21 (10, 5)5 (1, 2)5 (1, 2)2 (0, 1)2 (0, 1)4 (4, 0)0 (0, 0)10 (5, 2)0 (0, 0)7 (1, 3)
3-9 per HPF30 (22, 5)14 (9, 3)13 (9, 2)4 (4, 0)4 (4, 0)3 (2, 1)2 (1, 1)9 (7, 1)0 (0, 0)19 (14, 3)
>10 per HPF48 (32, 6)21 (10, 4)21 (10, 4)6 (5, 0)6 (5, 0)6 (4, 0)2 (2, 0)15 (13, 2)6 (5, 1)35 (22, 5)
    Growth patternInfiltrative89 (59, 12)37 (20, 7)36 (20, 6)10 (7, 1)10 (7, 1)12 (9, 1)4 (3, 1)30 (23, 3)6 (5, 1)56 (35, 9)
Pushing7 (3, 2)2 (0, 1)2 (0, 1)1 (1, 0)1 (1, 0)0 (0, 0)0 (0, 0)4 (2, 1)0 (0, 0)3 (1, 1)
    Vascular invasionYes11 (6, 0)6 (3, 0)6 (3, 0)0 (0, 0)0 (0, 0)1 (1, 0)0 (0, 0)4 (2, 0)0 (0, 0)6 (3, 0)
No84 (55, 16)33 (17, 9)32 (17, 8)12 (9, 1)12 (9, 1)11 (8, 1)4 (3, 1)28 (21, 5)6 (5, 1)54 (34, 11)
Immunohistochemical
    Ki-67≤10% positive cells10 (3, 4)4 (1, 2)4 (1, 2)0 (0, 0)0 (0, 0)2 (1, 1)1 (0, 1)4 (1, 1)0 (0, 0)5 (1, 3)
>10% positive cells69 (46, 9)26 (13, 5)26 (13, 5)11 (9, 0)11 (9, 0)10 (8, 0)3 (3, 0)22 (16, 4)3 (2, 1)43 (27, 6)
    p53≤40% positive cells68 (41, 12)30 (15, 7)30 (15, 7)7 (4, 1)7 (4, 1)7 (5, 1)3 (2, 1)24 (17, 3)5 (4, 1)45 (25, 10)
>40% positive cells19 (14, 4)5 (2, 2)4 (2, 1)4 (4, 0)4 (4, 0)3 (3, 0)0 (0, 0)7 (5, 2)0 (0, 0)8 (6, 1)
    p27≤30% positive cells45 (31, 5)17 (10, 2)16 (10, 1)4 (4, 0)4 (4, 0)8 (5, 1)3 (2, 1)16 (12, 2)2 (2, 0)25 (18, 2)
>30% positive cells45 (25, 11)18 (7, 7)18 (7, 7)8 (5, 1)8 (5, 1)4 (3, 0)1 (1, 0)15 (9, 3)3 (2, 1)30 (15, 9)
    Bcl-2≤30% positive cells84 (53, 15)32 (16, 8)31 (16, 7)10 (7, 1)10 (7, 1)11 (8, 1)4 (3, 1)31 (22, 5)5 (4, 1)50 (30, 10)
>30% positive cells8 (4, 1)4 (1, 1)4 (1, 1)2 (2, 0)2 (2, 0)1 (1, 0)0 (0, 0)1 (0, 0)0 (0, 0)6 (3, 1)
    Vessel density≤30 vessels per HPF67 (39, 13)30 (13, 8)29 (13, 7)10 (7, 1)10 (7, 1)7 (5, 1)3 (2, 1)20 (14, 3)4 (3, 1)46 (25, 10)
>30 vessels per HPF23 (17, 2)7 (5, 1)7 (5, 1)2 (2, 0)2 (2, 0)4 (3, 0)0 (0, 0)10 (7, 1)1 (1, 0)10 (8, 1)
    IGF-1R≤50% positive cells69 (42, 14)31 (14, 8)31 (14, 8)9 (7, 1)9 (7, 1)7 (5, 1)3 (2, 1)22 (16, 4)3 (2, 1)46 (25, 11)
>50% positive cells18 (12, 1)4 (4, 0)4 (4, 0)2 (1, 0)2 (1, 0)4 (3, 0)0 (0, 0)8 (4, 1)2 (2, 0)8 (7, 0)
  • NOTE: (x, x), figures in parenthesis represent MFH and liposarcoma.

  • Abbreviation: HPF, high power field.